Advertisement

CMV Infection and its Prevention with Specific Immunoglobulins

  • W. G. Ho
  • D. J. Winston
  • R. E. Champlin
  • R. P. Gale
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)

Abstract

Patients undergoing bone marrow transplantation for hematologic disorders are severely immunocompromised by the intensive chemotherapy and total body irradiation used in preparation for the transplant. Interstitial pneumonia occurs as a complication in approximately 40% of all bone marrow transplant recipients and is fatal in 70% of cases (1–3). Cytomegalovirus (CMV) is the most common pathogen associated with the interstitial pneumonia and can be identified in 50–70% of cases.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Winston DJ, Bryson YJ, Ho WG, Territo MD, Golde DW, Gale RP. Interstitial pneumonia and cytomegalovirus infection after bone marrow transplantation. In: Gale RP, Fox GE, eds. Biology of bone marrow transplantation, New York, Academic Press, 1980: 83–95.Google Scholar
  2. 2.
    Winston DJ, Ho WG, Champlin RE, Gale RP. Treatment and prevention of interstitial pneumonia associated with bone marrow transplantation. In: Gale RP, Fox GE, eds. Recent advances in bone marrow transplantation. UCLA Symposia on Molecular and Cellular Biology, Vol. 7, New York: Alan R. Liss Inc. (in press).Google Scholar
  3. 3.
    Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation - A review of ten years’ experience. Rev Infect Dis 1982; 4: 1119–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Kraemer KG, Neiman PE, Reeves WC, Thomas ED. Prophylactic adenine arabinoside following marrow transplantation. Transplant Proc 1978; 10: 237–40.PubMedGoogle Scholar
  5. 5.
    Meyers JD, McGuffin RW, Neiman PE, Singer JW, Thomas ED. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis 1980; 141: 555–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections: A randomized double blind controlled trial in bone marrow transplant recipients. N Engl J Med 1981; 305: 63–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Meyers JD, McGuffin RW, Bryson YJ, Cantell K, Thomas ED. Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis 1982; 146: 80–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Wade JC, Hintz M, McGuffin RW, Springmeyer SC, Connor JD, Meyers JD. Treatment of cytomegalovirus pneumonia with high dose acyclovir. Am J Med (Suppl) 1982; 73: 249–56.CrossRefGoogle Scholar
  9. 9.
    Winston DJ, Pollard RB, Ho WG, et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Am Intern Med 1982; 97: 11–8.CrossRefGoogle Scholar
  10. 10.
    Winston DJ, Ho WG, Ramussen LE, et al. Use of intravenous immune globulin in patients receiving bone marrow transplants. J Clin Immunol (Suppl) 1982; 2: 425–75.Google Scholar
  11. 11.
    Gale RP. Current status of bone marrow transplantation in acute leukemia. Transplant Proc 1979; 9: 1920–3.Google Scholar
  12. 12.
    Gale RP, Ho WG, Feig SA, Champlin RE. Prevention of graft rejection following bone marrow transplantation. Blood 1981; 57: 9–12.PubMedGoogle Scholar
  13. 13.
    Feig SA, Champlin R, Arenson E, et al. Improved survival following bone marrow transplantation in aplastic anemia. Br J Haematol 1983; 54: 509–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Casey HL. Adaptation of laboratory branch complement-fixation method to micro technique. Public monograph no 74 Washington DC: Government Printing Office, 1965.Google Scholar
  15. 15.
    Howell CL, Miller MJ, Martin WJ. Comparison of rates of virus isolation from leukocyte populations separated from blood by conventional and ficoll-paque/macrodex methods. J Clin Microbiol 1979; 10: 533–7.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Meyers JD, Leszczynski J, Zaia JA, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98: 442–6.PubMedCrossRefGoogle Scholar
  17. 17.
    O’Reilly RJ, Reich L, Gold J, et al. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation - Preliminary results. Transplant Proc 1983; 15: 1405–11.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • W. G. Ho
  • D. J. Winston
  • R. E. Champlin
  • R. P. Gale

There are no affiliations available

Personalised recommendations